MPL

Across TCGA pan-cancer cohorts, MPL Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated MPL data layer compared with 25 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MPL Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MPL expression acts as an unfavorable survival marker.

LUAD, STAD, and BLCA are the cancer types where MPL Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.158	0.750	<.001	24	view →
STAD	OS	Median	All	0.220	0.669	.002	12	view →
BLCA	DFS	Median	III,IV	0.163	0.576	<.001	12	view →
SKCM	OS	Median	All	0.245	0.781	.008	10	view →
LUSC	OS	Median	All	0.326	0.732	.005	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
COAD	OS	Median	All	0.500	0.808	.023	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

MPL–LUAD (OS)

Open the LUAD breakdown →